Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: Results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW)

International Journal of Stroke

Volumn 9, Issue A100, 2014, Pages 93-101

  Rha, Joung Ho ^a   Shrivastava, Vasantha Padma ^b   Wang, Yongjun ^c   Lee, Kim En ^d   Ahmed, Niaz ^e   Bluhmki, Erich ^f   Hermansson, Karin ^g   Wahlgren, Nils ^e  

^a Inha University Hospital   (South Korea)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g Boehringer Ingelheim AB   (Sweden)

Author keywords

Acute stroke; Haemorrhage; Ischaemic stroke; Monitoring; Safety; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHINA; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN COOPERATIVE ACUTE STROKE STUDY II SCORE; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; FUNCTIONAL INDEPENDENCE MEASURE; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SINGAPORE; SOUTH KOREA; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; INTERNATIONAL COOPERATION; RISK; STROKE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84905961057     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00895.x     Document Type: Article

References (27)

1. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
2. Hacke W, Kaste M, Fieschi C etal. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
3. Hacke W, Kaste M, Fieschi C etal. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352:1245-1251.
4. Clark WM, Wissman S, Albers GW etal. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5h after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282:2019-2026.
5. Clark WM, Albers GW, Madden KP etal. The rtPA (alteplase) 0- to 6-h acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31:811-816.
6. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4.5h after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
7. Wahlgren N, Ahmed N, Davalos A etal. Thrombolysis with alteplase 3-4.5h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372:1303-1309.
8. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5h after acute ischemic stroke: a metaanalysis. Stroke 2009; 40:2438-2441.
9. Ahmed N, Wahlgren N, Grond M etal. Implementation and outcome of thrombolysis with alteplase 3-4.5h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9:866-874.
10. Lees KR, Bluhmki E, von Kummer R etal. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695-1703.
11. Kaste M, Thomassen L, Grond M etal. Thrombolysis for acute ischemic stroke: a consensus statement of the 3rd Karolinska Stroke Update, October 30-31, 2000. Stroke 2001; 32:2717-2718.
12. Adams HP Jr, del Zoppo G, Alberts MJ etal. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-1711.
13. The European Stroke Initiative Executive Committee and European Stroke Initiative Writing Group. The European Stroke Initiative Executive Committee and European Stroke Initiative Writing Group: European stroke initiative recommendations for stroke management - update 2003. Cerebrovasc Dis 2003; 16:311-337.
14. Wahlgren N, Ahmed N, Davalos A etal. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275-282.
15. Wahlgren N, Ahmed N, Eriksson N etal. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke 2008; 39:3316-3322.
16. Wardlaw JM, Zoppo G, Yamaguchi T etal. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; CD000213.
17. SITS International. Safe implementation of thrombolysis in stroke. Available at https://sitsinternational.org/
18. Larrue V, von Kummer RR, Muller A etal. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32:438-441.
19. Berger C, Fiorelli M, Steiner T etal. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001; 32:1330-1335.
20. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17:857-872.
21. Yamaguchi T, Mori E, Minematsu K etal. Alteplase at 0.6mg/kg for acute ischemic stroke within 3hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:1810-1815.
22. Mori E, Minematsu K, Nakagawara J etal. Effects of 0.6mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41:461-465.
23. Nakagawara J, Minematsu K, Okada Y etal. Thrombolysis with 0.6mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41:1984-1989.
24. Zhou XY, Wang SS, Collins ML etal. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci 2010; 17:988-992.
25. Salam KA, Ummer K, Kumar VG etal. Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008. J Clin Neurosci 2009; 16:1276-1278.
26. Sharma VK, Tsivgoulis G, Tan JH etal. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis 2010; 19:424-430.
27. Enhanced Control of Hypertension and Thrombolysis Stroke Study (Enchanted). Available at http://clinicaltrials.gov/ct2/show/NCT01422616 (accessed February 2012).